Are Chamath Palihapitiya’s 4 New Biotech SPACs Worth a Look?
The ‘SPAC king’ shifts focus to biotech with his latest idea: four DNA-dubbed offerings Q2 2021 hedge fund letters, conferences and more Tech firebrand Chamath Palihapitiya is still looking for merger candidates for two of his six blank-check companies. But that hasn’t stopped the ace investor from filing for four more special purpose acquisition companies (SPACs), focusing on biotech. Palihapitiya filed paperwork with the Securities and Exchange Commission (SEC) for Social Capital Suvretta Holdings Corp I (NASDAQ:DNAA), Social Capital Suvretta Holdings Corp II (NASDAQ:DNAB), Social Capital Su...